Alpha 2.0
Login Register
» Authors » Daisuke Tomimoto

Daisuke Tomimoto

Explore the profile of Daisuke Tomimoto including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 61
Followers 0
Related Specialties
Biochemistry
Pharmacology
Veterinary Medicine
Top 10 Co-Authors
Takeshi Ohta
Yukihito Ishii
Chihiro Okuma
Makoto Kakutani
Nobuya Ogawa
Hironobu Tadaki
Yasuko Mera
Takashi Kawai
Tomohiko Sasase
Akio Kobayashi
Published In
Biol Pharm Bull
J Pharmacol Exp Ther
J Diabetes Res
Exp Eye Res
J Vet Med Sci
Affiliations
Soon will be listed here.
Recent Articles
1.
A pyruvate dehydrogenase kinase inhibitor prevents retinal cell death and improves energy metabolism in rat retinas after ischemia/reperfusion injury
Sato K, Mochida S, Tomimoto D, Konuma T, Kiyota N, Tsuda S, et al.
Exp Eye Res . 2020 Mar; 193:107997. PMID: 32165157
We aimed to assess the neuroprotective effect of a pyruvate dehydrogenase kinase (PDK) inhibitor, Nov3r after ischemia/reperfusion (IR) injury in rats. IR injury was induced by applying 150 mmHg of...
2.
A Novel TNF-α Converting Enzyme (TACE) Selective Inhibitor JTP-96193 Prevents Insulin Resistance in KK-A Type 2 Diabetic Mice and Diabetic Peripheral Neuropathy in Type 1 Diabetic Mice
Maekawa M, Tadaki H, Tomimoto D, Okuma C, Sano R, Ishii Y, et al.
Biol Pharm Bull . 2019 Nov; 42(11):1906-1912. PMID: 31685773
Tumor necrosis factor-α (TNF-α) converting enzyme/a disintegrin and metalloproteinase domain-containing protein 17 (TACE/ADAM17) is a key sheddase that releases TNF-α from its inactive precursor and is thought as a new...
3.
JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 inhibitor, improves glucose metabolism in diet-induced obesity and genetic T2DM mice
Tomimoto D, Okuma C, Ishii Y, Kobayashi A, Ohta T, Kakutani M, et al.
J Pharmacol Sci . 2015 Sep; 129(1):51-8. PMID: 26354408
Type 2 diabetes mellitus (T2DM) arises primarily due to lifestyle factors and genetics. A number of lifestyle factors are known to be important in the development of T2DM, including obesity....
4.
Pharmacological characterization of [trans-5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl]acetic acid monobenzenesulfonate (JTT-553), a novel acyl CoA:diacylglycerol...
Tomimoto D, Okuma C, Ishii Y, Akiyama Y, Ohta T, Kakutani M, et al.
Biol Pharm Bull . 2015 Mar; 38(2):263-9. PMID: 25747985
Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 is an enzyme that catalyzes the final step in triglyceride (TG) synthesis. This enzyme is considered to be a potential therapeutic target for obesity and...
5.
JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, reduces food preference for fat
Mera Y, Hata T, Ishii Y, Tomimoto D, Kawai T, Ohta T, et al.
J Diabetes Res . 2014 Jun; 2014:583752. PMID: 24959597
Microsomal triglyceride transfer protein (MTP) is involved in the assembly and secretion of triglyceride-rich lipoproteins from enterocytes and hepatocytes. JTT-130 is a novel intestine-specific MTP inhibitor, which has been shown...
6.
Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents
Fox B, Sugimoto K, Iio K, Yoshida A, Zhang J, Li K, et al.
J Med Chem . 2014 Mar; 57(8):3464-83. PMID: 24670009
The discovery and optimization of a series of acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors based on a pyrimido[4,5-b][1,4]oxazine scaffold is described. The SAR of a moderately potent HTS hit was...
7.
Diabetic peripheral neuropathy in Spontaneously Diabetic Torii-Lepr(fa) (SDT fatty) rats
Yamaguchi T, Sasase T, Mera Y, Tomimoto D, Tadaki H, Kemmochi Y, et al.
J Vet Med Sci . 2012 Aug; 74(12):1669-73. PMID: 22850562
Spontaneously Diabetic Torii (SDT) rat is a hereditary model of diabetes. Although the SDT rat shows severe diabetic complications, the onset of hyperglycemia is late. SDT fatty rat, established by...
8.
JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner
Hata T, Mera Y, Ishii Y, Tadaki H, Tomimoto D, Kuroki Y, et al.
J Pharmacol Exp Ther . 2010 Dec; 336(3):850-6. PMID: 21139060
The microsomal triglyceride transfer protein (MTP) takes part in the mobilization and secretion of triglyceride-rich lipoproteins from enterocytes and hepatocytes. In this study, we investigated the effects of diethyl-2-({3-dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl) amino]...